Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Change in Taxes (2017 - 2020)

Avalo Therapeutics (AVTX) has disclosed Change in Taxes for 4 consecutive years, with $839000.0 as the latest value for Q2 2020.

  • For the quarter ending Q2 2020, Change in Taxes rose 298.73% year-over-year to $839000.0, compared with a TTM value of $839000.0 through Mar 2021, up 146.25%, and an annual FY2020 reading of $288000.0, up 119.45% over the prior year.
  • Change in Taxes was $839000.0 for Q2 2020 at Avalo Therapeutics, up from -$551000.0 in the prior quarter.
  • Across five years, Change in Taxes topped out at $3.2 million in Q3 2017 and bottomed at -$970852.0 in Q4 2017.
  • Average Change in Taxes over 4 years is $69972.6, with a median of -$190199.0 recorded in 2018.
  • The sharpest move saw Change in Taxes plummeted 3040.65% in 2019, then skyrocketed 298.73% in 2020.
  • Year by year, Change in Taxes stood at -$970852.0 in 2017, then soared by 83.23% to -$162790.0 in 2018, then plummeted by 184.28% to -$462783.0 in 2019, then surged by 281.29% to $839000.0 in 2020.
  • Business Quant data shows Change in Taxes for AVTX at $839000.0 in Q2 2020, -$551000.0 in Q1 2020, and -$462783.0 in Q4 2019.